Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
The Lancet. HIV|May 11, 2024
Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trialAnthony M Mills, Giuliano Rizzardini, Moti N Ramgopal, et al.
Infectious Diseases and Therapy|September 15, 2024
A Pooled Analysis of Eight Clinical Studies Suggests a Link Between Influenza-Like Symptoms and Pharmacodynamics of the Toll-Like Receptor-7 Agonist VesatolimodSharon A Riddler, Constance A Benson, Cynthia Brinson, et al.
Lancet (London, England)|February 7, 2026
Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trialAmy E Colson, Anthony M Mills, Moti N Ramgopal, et al.
Annals of Internal Medicine|December 22, 2025
Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Persons With HIV-1 : A Phase 2 Randomized StudyAmy E Colson, Gordon E Crofoot, Peter J Ruane, et al.
The Lancet. HIV|August 11, 2023
Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trialMoti N Ramgopal, Antonella Castagna, Charles Cazanave, et al.
The New England Journal of Medicine|July 29, 2026
Phase 3 Trial of Weekly Oral Islatravir-Lenacapavir for HIV-1 TreatmentJürgen K Rockstroh, Moti N Ramgopal, Adrian Curran Fàbregas, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 14, 2026
Safety and Tolerability of Oral Islatravir Once Monthly as Pre-Exposure Prophylaxis in Cisgender Men and Transgender Women Who Have an Elevated Likelihood of HIV-1 Exposure: Results From the IMPOWER-24 Randomized Phase 3 StudyRaphael J Landovitz, Yvett Pinedo, Federico Hinestrosa, et al.
Pageof 2